独立于RAF的MEK突变驱动耐火性囊瘤,但对ERK抑制有反应
Eli L Diamond1, Jean-Francois Emile2, Takeshi Fujino3
1Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cancer cell
|October 24, 2025
概括
在囊性瘤中,RAF独立的MEK1/2突变预测对MEK抑制剂的反应不佳. 用乌利克塞提尼布抑制ERK显示出治疗这些耐药病例的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 囊性瘤包括由MAPK信号突变驱动的单细胞/巨细胞谱系障碍.
- 像科比米提尼布这样的MEK1/2抑制剂被FDA批准用于成人囊细胞瘤.
研究的目的:
- 为了研究特定的MEK1/2突变对质细胞瘤治疗结果的影响.
- 确定MEK抑制剂耐药性的预测标记物,并探索替代治疗策略.
主要方法:
- 对前性注册表 (NCT03329274) 的分析.
- 在体内小鼠模型中研究MEK1E102_I103del突变的影响.
- 在患有MEK1E102_I103del-突变性质细胞瘤的患者中对ulixertinib的临床试验.
主要成果:
- 独立于RAF的MEK1/2突变与在MEK1/2抑制下更差的无进展生存相关.
- MEK1E102_I103del突变诱导了小鼠具有致命的质细胞类瘤,对ERK1/2抑制敏感.
- 在5名患有MEK1E102_I103del突变的患者中,有4名对MEK抑制剂耐药,对ulixertinib有反应.
结论:
- 瘤性MEK突变在体内显著影响囊性瘤的进展.
- 特定的MEK1/2突变类预测对MEK抑制的抗性.
- 阻断ERK是一种可行的治疗策略,用于克服MEK抑制剂在囊细胞瘤中的耐药性.
相关概念视频
MAPK Signaling Cascades
7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K


